

Des[®]

Desloratadine BP

Description

Desloratadine (**Des[®]**) is the primary active metabolite of Loratadine. It is a non-sedating, long-acting antihistamine. After oral administration, it produces selective peripheral H₁ receptor antagonist activity.

Mode of action

Desloratadine (**Des[®]**) selectively blocks peripheral H₁ receptors. It also appears to inhibit important cytokine and cellular activity and thus renders antiallergic and anti-inflammatory activities.

Pharmacokinetics

Plasma concentrations of Desloratadine (**Des[®]**) can be detected within 30 minutes of administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. It is moderately bound (83-87%) to plasma proteins. There is no evidence of clinically relevant drug accumulation following once daily dosing of desloratadine 5 mg to 20 mg for 14 days.

Composition

Des[®] 5 mg Tablet: Each film-coated tablet contains Desloratadine BP 5 mg.

Des[®] 60 ml Syrup: Each 5 ml syrup contains Desloratadine BP 2.5 mg.

Indications

Seasonal allergic rhinitis, chronic idiopathic urticaria.

Dosage & administration

Adult and adolescent over 12 years: 5 mg (1 tablet or 2 teaspoonful) once daily.

Child 6-11 years: 2.5 mg ($\frac{1}{2}$ tablet or 1 teaspoonful) once daily

Child 2-5 years: 1.25 mg or $\frac{1}{2}$ teaspoonful once daily.

Contraindications

Desloratadine is contraindicated in patients who are hypersensitive to loratadine or any of the excipients.

Side effects

In the recommended doses, undesirable effects with desloratadine are very low. The frequent side effects include fatigue, dry mouth and headache.

Use in pregnancy & lactation

The safe use of desloratadine during pregnancy has not been established. It is not to be used during pregnancy unless the potential benefits outweigh the risks. Desloratadine is excreted into breast milk, therefore its use is not recommended in breast-feeding women.

Precautions

In the case of severe renal and hepatic impairment, desloratadine should be used with caution.

Drug interactions

The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other drugs can not be fully excluded.

Overdosage

In the event of overdose, standard measures are considered to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended. Desloratadine is not eliminated by hemodialysis.

Storage

Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light.

Packaging

Des[®] Tablet: Each carton contains 15X4 tablets in blister pack.

Des[®] Syrup: Each carton contains a bottle having 60 ml syrup.



Manufactured by
Opsonin Pharma Limited
Rupatali, Barishal, Bangladesh.
® Registered Trade Mark.

828-02